Skip to content
Rapivab, Alpivab(peramivir)
Alpivab, Rapivab (peramivir) is a small molecule pharmaceutical. Peramivir was first approved as Rapivab on 2014-12-19. It is used to treat human influenza in the USA. It has been approved in Europe to treat human influenza.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
Trade Name
FDA
EMA
Rapivab
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Peramivir
Tradename
Company
Number
Date
Products
RAPIVABBioCryst PharmaceuticalsN-206426 RX2014-12-19
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
rapivabNew Drug Application2020-08-03
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
human influenzaEFO_0007328D007251J11.1
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Peramivir, Rapivab, Biocryst
87789972027-05-07U-1627, U-2622, U-3069
103910752027-02-12U-2622, U-3069
65628612023-12-16DP
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AH: Neuraminidase inhibitors, direct acting antivirals
— J05AH03: Peramivir
HCPCS
Code
Description
J2547
Injection, peramivir, 1 mg
Clinical
Clinical Trials
47 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
B-cell chronic lymphocytic leukemiaD015451C91.11711—10
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Graft vs host diseaseD006086D89.81—71——8
Myelodysplastic syndromesD009190D46131——4
Hodgkin diseaseD006689C81—31——4
Myeloid leukemia acuteD015470C92.0—21——3
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.0—21——3
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—21——3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938C95414———15
LymphomaD008223C85.9314———14
Non-hodgkin lymphomaD008228C85.913———4
Sickle cell anemiaD000755EFO_0000697D5722———3
Multiple myelomaD009101C90.0—3———3
Hematologic neoplasmsD019337—3———3
ThalassemiaD013789EFO_1001996D5611———2
T-cell lymphoma peripheralD016411C84.9—2———2
Waldenstrom macroglobulinemiaD008258C88.0—2———2
Renal cell carcinomaD002292—2———2
Show 12 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HemoglobinopathiesD006453D58.21————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePERAMIVIR
INNperamivir
Description
Peramivir is a member of the class of guanidines that is used (as its trihydrate) for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. It has a role as an antiviral drug and an EC 3.2.1.18 (exo-alpha-sialidase) inhibitor. It is a member of cyclopentanols, a member of acetamides, a member of guanidines and a 3-hydroxy monocarboxylic acid. It contains a peramivir hydrate.
Classification
Small molecule
Drug classantivirals: neuraminidase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N
Identifiers
PDB—
CAS-ID330600-85-6
RxCUI1598096
ChEMBL IDCHEMBL139367
ChEBI ID85202
PubChem CID154234
DrugBankDB06614
UNII ID9ZS94HQO3B (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,117 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
838 adverse events reported
View more details